For how we live.
28 articles published between November 12, 2025 and October 20, 2026.
A six-site randomised trial of point-of-care high-sensitivity troponin cut emergency-department length of stay by 47 minutes, with no change in 30-day heart attacks or cardiac deaths.
The phase 2 ROXAMI trial gave the oral HIF stabiliser roxadustat to 158 STEMI patients after stenting. Infarct size at 30 days was no smaller than with standard care. Later remodelling findings were exploratory.
Some heart attacks leave scar on an ECG or MRI but were never felt as one. In a long US cohort they made up more than 45% of heart attacks — and they still shortened survival.
The crushing chest pressure is real and common. But in a registry of more than a million patients, 42% of women arrived without chest pain, against 31% of men — and the gap was widest in the young.
In heart patients, randomised trials link influenza vaccination to fewer cardiovascular events and deaths. The effect is clearest in the highest-risk patients, and the largest trial stopped early.
In people with no heart disease, aspirin's benefit was small or absent and bleeding rose across three large trials. US guidance now advises against starting it at 60 or older.
Colder days track with more heart attacks in nationwide data, and the sharpest signal is the day after heavy snowfall — a rise seen in men but not women, pointing to the shovel as much as the temperature.
A Mediterranean diet rich in extra-virgin olive oil cut cardiovascular events in a Spanish trial, and US cohorts link over half a tablespoon a day to less heart disease — the biggest signal in what it replaces.
Two trials found low-dose colchicine cut cardiovascular events, and the FDA approved it for heart risk in 2023. Then the largest trial found nothing, leaving the question genuinely unsettled.
Pooled across 85 trials, exercise-based cardiac rehab cut later heart attacks and hospital admissions but barely moved death rates within a year — a real benefit, and a narrower one than the usual pitch.
Large randomised trials mostly find no cardiovascular benefit from ordinary fish-oil capsules. One high-dose prescription drug is the striking exception, and the case for brain protection is weak.
TARGET-CTCA randomised 3,170 emergency patients whose troponin had cleared them of a heart attack. Outpatient CT angiography-guided care matched standard care on later infarction or cardiac death.
PRESC1SE-MI covered 67,624 chest-pain presentations at 19 hospitals. The one-hour troponin pathway matched the three-hour one on safety, and median length of stay was identical: 309 minutes.
STAREE randomised 9,971 Australians aged 70 and over to atorvastatin or placebo. Cardiovascular events fell by 30%. Death, dementia and persistent disability, taken together, did not move.
SWITCH-SWEDEHEART randomised regions rather than patients. Over 17,095 people, a default prasugrel policy did not lower ischaemic events against ticagrelor, but major bleeding was lower.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
The Fifth Universal Definition of Myocardial Infarction drops the numbered types, keeps sex-specific troponin thresholds, and proposes ICD-11 codes so the categories can be counted.
ABYSS and SMART-DECISION together cover 6,238 stable patients. Discontinuation cleared both noninferiority margins, though the authors say the primary endpoint's composition limits what it shows.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
Stanford's SleepFM, published in Nature Medicine in January 2026, is the most consequential sleep paper of the year. Its own limitations section explains why it is not yet a clinical test.
Genetic and trial evidence establishes LDL as causal for atherosclerosis. The same kinds of evidence, applied to HDL, found that raising it does not lower heart attack risk.
Both morning and evening chronotypes showed elevated risk against the middle ground, and the effect nearly doubled in people who also had sleep apnea.
Fine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
Pooling 11 cohort studies, researchers found a consistent cardiovascular signal in Asian and North American cohorts. European cohorts showed no elevated risk at all, a geographic split the analysis can't explain.
Pooled data across 38 studies found higher coffee intake linked to a higher risk of heart attack — but a lower risk of stroke and irregular heartbeat, with a separate benefit for people with high blood pressure.
In 2,286 patients with sleep apnea undergoing major surgery, a measure of how deeply and how long oxygen fell — not the apnea-hypopnea index — tracked 30-day cardiovascular events and death.
Cedars-Sinai counted a 118% rise in general-illness visits and a 46% rise in heart attack visits over the 90 days after the fires started. Abnormal blood results more than doubled.
An individual-patient meta-analysis of 17,801 patients found a hazard ratio of 0.97 for death, reinfarction or heart failure — a result precise enough to make the question look settled.